Shares of Actuate Therapeutics, Inc. (NASDAQ:ACTU - Get Free Report) were down 4.6% during trading on Wednesday . The stock traded as low as $6.23 and last traded at $6.44. Approximately 52,973 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 51,906 shares. The stock had previously closed at $6.75.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on ACTU shares. Craig Hallum began coverage on shares of Actuate Therapeutics in a report on Tuesday, April 22nd. They issued a "buy" rating and a $21.00 target price on the stock. HC Wainwright boosted their target price on shares of Actuate Therapeutics to $20.00 and gave the stock a "buy" rating in a report on Tuesday, June 3rd.
View Our Latest Analysis on Actuate Therapeutics
Actuate Therapeutics Stock Performance
The company has a 50 day simple moving average of $9.14 and a two-hundred day simple moving average of $8.32.
Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.06).
Institutional Investors Weigh In On Actuate Therapeutics
Several institutional investors have recently modified their holdings of ACTU. Sigma Planning Corp bought a new stake in shares of Actuate Therapeutics in the 4th quarter valued at approximately $128,000. Freestone Capital Holdings LLC bought a new stake in shares of Actuate Therapeutics in the 4th quarter valued at approximately $80,000. BIOS Capital Management LP bought a new stake in shares of Actuate Therapeutics in the 4th quarter valued at approximately $78,753,000. Envestnet Asset Management Inc. bought a new stake in shares of Actuate Therapeutics in the 4th quarter valued at approximately $83,000. Finally, Voss Capital LP bought a new stake in shares of Actuate Therapeutics in the 4th quarter valued at approximately $440,000.
About Actuate Therapeutics
(
Get Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Read More
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
